Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Danwang Medical Technology

Request full access

A medical company focusing on organoid technology

Huangpu, ChinaFounded 2019Biotech & Life Sciences

About Danwang Medical Technology

Established in Shanghai in 2019, Danwang Medical Technology operates at the forefront of regenerative medicine, specializing in organoid technology. The company was founded by Li Junqiang, Hua Guoqiang, and Hans Clevers. Danwang Medical focuses on developing and manufacturing organoid models to advance disease diagnosis, support new drug screening, and aid in tumor marker identification. The company provides these high-fidelity organoid models to the biopharmaceutical sector, research institutions, and hospitals, facilitating new drug development and personalized treatment strategies.

The core of Danwang Medical's business is its proprietary organoid technology platform. This platform allows for the creation of three-dimensional cell culture models, or "mini-organs," that closely mimic the characteristics of human organs and tumors. The company has successfully developed culture systems for a wide range of organoids, including those for the lung, pancreas, breast, stomach, intestine, and liver. Its services encompass providing these organoid models for scientific research, drug screening, toxicology evaluation, and immune co-culture evaluations. A key application is in oncology, where patient-derived tumor organoids are used for drug sensitivity testing, helping to guide personalized cancer treatment within a rapid timeframe, typically around two weeks.

The company's business model is centered on providing both products and services. It offers an extensive organoid biobank, featuring models from various tumor and normal tissues, as well as specific genetic mutation libraries like KRAS and HER2. For its biopharma clients, Danwang provides a comprehensive R&D service platform to validate drug candidates. Additionally, it develops and supplies IVD reagents and automated equipment to help clients efficiently conduct organoid-related research. Financially, Danwang Medical is a venture capital-backed entity, having secured multiple rounds of funding. Its initial seed round in February 2021 involved investors such as Co-win Ventures, Delian Capital, and Kunlun Capital. Subsequent funding rounds, including a Series A in October 2021 and a later-stage VC round in December 2024, have supported its growth and revenue generation.

Source: Dealroom company data

Danwang Medical Technology in the Huangpu ecosystem

Live from Dealroom

The Danwang Medical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Delian Capital
  • Kunlun Capital
  • Sinowisdom
  • Cowin Venture
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Huangpu HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Danwang Medical Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Danwang Medical Technology on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.